Croda acquires Alban Muller
Croda acquires Alban Muller, a leader in natural active ingredients
2 March 2021
Croda International Plc ("Croda"), which uses smart science to create high performance ingredients and technologies that improve lives, today announces it has agreed to acquire the worldwide business activities of Alban Muller for a total consideration of €25m.
With an annual revenue of €18m for the year to 30 June 2020, Alban Muller is based in France and is a leader in the creation and supply of natural and botanical ingredients for the global beauty industry. The acquisition expands Croda's portfolio of sustainable active ingredients for customers in personal care markets, complementing our industry-leading positions with Sederma and Crodarom.
Steve Foots, Croda Chief Executive Officer, said: "The acquisition of Alban Muller enhances Croda's position as a world leader in natural and botanical actives, helping us meet the increasing demand from customers looking for ingredients of natural origin to improve the sustainability profile of their products."
The transaction is subject to customary pre closing conditions and is expected to close by the end of Q1 2021.
For more information, please contact:
Investors: David Bishop, Croda +44 7823 874428
Media: Charlie Armitstead, Teneo +44 7703 330269
About Croda - www.croda.com
Established in 1925, Croda is the name behind sustainable, high performance ingredients and technologies in some of the world's most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere.
Croda is a FTSE 100 company with over 5,600 passionate and innovative employees, working across manufacturing sites and offices around the world with a shared Purpose to use Smart Science to Improve Lives™. As part of this Purpose, and with around two thirds of its organic raw materials already from bio-based sources, Croda has committed to be the most sustainable supplier of innovative ingredients, becoming Climate, Land and People Positive by 2030.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 12 hours ago Johnson Matthey
- 13 hours ago Galliford Try
- 13 hours ago Galliford Try
- 13 hours ago Centrica
- 14 hours ago Smith & Nephew